492 related articles for article (PubMed ID: 27199429)
1. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
[TBL] [Abstract][Full Text] [Related]
2. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
Mendoza P; Gruell H; Nogueira L; Pai JA; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Lorenzi JCC; Cohen YZ; Wyen C; Kümmerle T; Karagounis T; Lu CL; Handl L; Unson-O'Brien C; Patel R; Ruping C; Schlotz M; Witmer-Pack M; Shimeliovich I; Kremer G; Thomas E; Seaton KE; Horowitz J; West AP; Bjorkman PJ; Tomaras GD; Gulick RM; Pfeifer N; Fätkenheuer G; Seaman MS; Klein F; Caskey M; Nussenzweig MC
Nature; 2018 Sep; 561(7724):479-484. PubMed ID: 30258136
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
[TBL] [Abstract][Full Text] [Related]
5. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
[TBL] [Abstract][Full Text] [Related]
6. Combination anti-HIV antibodies provide sustained virological suppression.
Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
[TBL] [Abstract][Full Text] [Related]
7. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
8. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
Jaworski JP; Cahn P
Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated prevention and treatment of HIV-1 infection.
Gruell H; Klein F
Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
[TBL] [Abstract][Full Text] [Related]
10. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
Caskey M; Schoofs T; Gruell H; Settler A; Karagounis T; Kreider EF; Murrell B; Pfeifer N; Nogueira L; Oliveira TY; Learn GH; Cohen YZ; Lehmann C; Gillor D; Shimeliovich I; Unson-O'Brien C; Weiland D; Robles A; Kümmerle T; Wyen C; Levin R; Witmer-Pack M; Eren K; Ignacio C; Kiss S; West AP; Mouquet H; Zingman BS; Gulick RM; Keler T; Bjorkman PJ; Seaman MS; Hahn BH; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC; Klein F
Nat Med; 2017 Feb; 23(2):185-191. PubMed ID: 28092665
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.
Cohen YZ; Butler AL; Millard K; Witmer-Pack M; Levin R; Unson-O'Brien C; Patel R; Shimeliovich I; Lorenzi JCC; Horowitz J; Walsh SR; Lin S; Weiner JA; Tse A; Sato A; Bennett C; Mayer B; Seaton KE; Yates NL; Baden LR; deCamp AC; Ackerman ME; Seaman MS; Tomaras GD; Nussenzweig MC; Caskey M
PLoS One; 2019; 14(8):e0219142. PubMed ID: 31393868
[TBL] [Abstract][Full Text] [Related]
12. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
Tuyishime M; Garrido C; Jha S; Moeser M; Mielke D; LaBranche C; Montefiori D; Haynes BF; Joseph S; Margolis DM; Ferrari G
J Clin Invest; 2020 Oct; 130(10):5157-5170. PubMed ID: 32584790
[TBL] [Abstract][Full Text] [Related]
13. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
Klein F; Halper-Stromberg A; Horwitz JA; Gruell H; Scheid JF; Bournazos S; Mouquet H; Spatz LA; Diskin R; Abadir A; Zang T; Dorner M; Billerbeck E; Labitt RN; Gaebler C; Marcovecchio P; Incesu RB; Eisenreich TR; Bieniasz PD; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC
Nature; 2012 Dec; 492(7427):118-22. PubMed ID: 23103874
[TBL] [Abstract][Full Text] [Related]
14. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker LG; Hoelscher M; Maboko L; Makhema J; Robb ML; Abdool Karim S; Abdool Karim Q; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
PLoS Pathog; 2016 Jul; 12(7):e1005742. PubMed ID: 27434311
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.
Stoddart CA; Galkina SA; Joshi P; Kosikova G; Long BR; Maidji E; Moreno ME; Rivera JM; Sanford UR; Sloan B; Cieplak W; Wrin T; Chan-Hui PY
Virology; 2014 Aug; 462-463():115-25. PubMed ID: 24971704
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.
Caskey M; Klein F; Nussenzweig MC
Nat Med; 2019 Apr; 25(4):547-553. PubMed ID: 30936546
[TBL] [Abstract][Full Text] [Related]
17. [Trispecific broadly neutralizing antibodies for HIV immunoprophylaxis and immunotherapy?].
Barin F; Stefic K
Med Sci (Paris); 2018 Feb; 34(2):109-111. PubMed ID: 29451475
[No Abstract] [Full Text] [Related]
18. HIV: advancing the antibody approach.
Bird L
Nat Rev Immunol; 2013 Dec; 13(12):846-7. PubMed ID: 24409525
[No Abstract] [Full Text] [Related]
19. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.
Lu CL; Murakowski DK; Bournazos S; Schoofs T; Sarkar D; Halper-Stromberg A; Horwitz JA; Nogueira L; Golijanin J; Gazumyan A; Ravetch JV; Caskey M; Chakraborty AK; Nussenzweig MC
Science; 2016 May; 352(6288):1001-4. PubMed ID: 27199430
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses to the HIV-1 envelope high mannose patch.
Daniels CN; Saunders KO
Adv Immunol; 2019; 143():11-73. PubMed ID: 31607367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
